CD138, Syndecan-1 (B-A38)Catalog number: CD138A-5
The antibody B-A38 (like B-B4) stains all plasma cells and all plasma cell lines, which have been tested so far. No other leukocytes are stained in peripheral blood or bone marrow. However, some ALL cell lines express CD138 weekly, and some epithelia and endothelia may be stained in immunohistochemistry. Syndecan 1, CD138, is a heparan-rich glycoprotein (MW 200 kDa), which is expressed on the cell membrane of plasma cells. CD138 functions as a receptor for extracellular matrix proteins like collagen, fibronectin and thrombospondin. Human CD138, Syndecan 1.
Immunogen: U266 cell line
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains BSA and 0.09 % sodium azide**. The volume is sufficient for at least 50 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.
Purification Method: Antibody solution in stabilizing phosphate buffer pH 7.3. Contains BSA and 0.09 % sodium azide**. The volume is sufficient for at least 50 immunohistochemical tests (100 µl working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art. No. PU002, if further dilution is required.
Secondary Reagents: We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity: Human, others not tested
Incubation Time: 60 min at RT
Working Concentration: (RTU) neat
Pre-Treatment: No protease necessary for IHC, but heat pre-treatment with citrate buffer (Art. No. DE000) or EDTA buffer pH 9 (Art. No. DE006) may enhance staining intensity.
Positive Control: Tonsil
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Borset M., et al. (1993) Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br. J. Haem. 85; 446 ff. 2. Wijdenes J., et al. (1996) A plasmocyte selective monoclonal antibody (B-B4) recognises Syndecan-1. Br. J. Haem. 94; 318-323. 3. Inki. P. and Jalkanen M. (1996) The role of syndecan-1 in malignancies. Ann. Med. 28(1); 63-67. 4. Anttonen A., et al. (1999) Syndecan-1 expression has prognostic significance in head and neck carcinoma. Brit J. Cancer 79; 558-564. 5. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G,Sasisekharan R, Naggi A, Torri G, Casu B, Vlodavsky I, Suva LJ, Epstein J,Yaccoby S, Shaughnessy JD Jr, Barlogie B, Sanderson RD. (2007) The syndecan-1 heparan sulfate proteoglycan
Safety Datasheet(s) for this product: